Department of Neonatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 200032, China.
Department of Neonatology, Maternal and Child Health Hospital of Hubei Province, Hubei, 430070, China.
BMC Pediatr. 2021 Jun 5;21(1):261. doi: 10.1186/s12887-021-02737-6.
Neonatal hypoxic-ischemic encephalopathy (HIE) affects as many as 100,000 infants each year in China. Therapeutic hypothermia reduces HIE related mortality and long-term neurodevelopmental disabilities. National guidelines for HIE management were published a decade ago. This study aimed to investigate the current status of HIE diagnosis and treatment in China.
This prospective cross-sectional national survey used a questionnaire evaluating practices related to HIE management. Descriptive statistics and Chi-square or Fisher's exact test were used, and a p-value of < 0.05 was considered significant.
The 273 hospitals that completed the survey were located in 31 of the 34 provincial districts in China. Eighty-eight percent of the hospitals were Level III hospitals, and 74% treated 10 or more HIE cases annually. Awareness rates of the national guidelines for HIE diagnosis, HIE treatment, and therapeutic hypothermia protocol were 85, 63, and 78%, respectively. Neurological manifestations and blood gas were used as HIE diagnostic criteria by 96% (263/273) and 68% (186/273) of the hospitals, respectively. Therapeutic hypothermia was used in 54% (147/273) of hospitals. The percentage of general hospitals that implemented therapeutic hypothermia (43%, 71/165) was significantly lower than that in maternity and infant hospitals (67%, 49/73) (χ = 11.752, p = 0.001) and children's hospitals (77%, 27/35) (χ = 13.446, p < 0.001). Reasons for not providing therapeutic hypothermia included reduction of HIE cases in recent years (39%), high cost of cooling devices and treatment (31%), lack of training (26%), and safety concerns (4%). Among the hospitals that provided therapeutic hypothermia, 27% (39/147) were in full compliance with the recommended protocol. Eighty-one percent (222/273) of the hospitals treated HIE infants with putative neuroprotective agents alone or in combination with cooling. Ninety-one percent of the hospitals had long-term neurodevelopmental follow-up programs for infants with HIE.
There is significant heterogeneity in HIE diagnosis and treatment in China. Therapeutic hypothermia has not become a standard of care for neonatal HIE nationwide. Unproven agents are widely used for HIE treatment. Nationwide standardization of HIE management and dissemination of therapeutic hypothermia represent the opportunities to reduce mortality and improve long-term neurodevelopmental outcomes of children affected by HIE.
新生儿缺氧缺血性脑病(HIE)每年影响中国多达 10 万名婴儿。亚低温治疗可降低 HIE 相关死亡率和长期神经发育障碍。HIE 管理的国家指南在十年前发布。本研究旨在调查中国 HIE 诊断和治疗的现状。
这项前瞻性的全国性横断面调查使用了一份评估 HIE 管理相关实践的问卷。采用描述性统计和卡方检验或 Fisher 精确检验,p 值<0.05 被认为具有统计学意义。
完成调查的 273 家医院分布在中国 34 个省级行政区中的 31 个。88%的医院为三级医院,74%的医院每年治疗 10 例或以上的 HIE 病例。HIE 诊断、HIE 治疗和亚低温治疗方案的国家指南知晓率分别为 85%、63%和 78%。96%(263/273)和 68%(186/273)的医院分别将神经学表现和血气作为 HIE 的诊断标准。54%(147/273)的医院使用了亚低温治疗。实施亚低温治疗的综合医院比例(43%,71/165)明显低于妇产科医院(67%,49/73)(χ²=11.752,p=0.001)和儿童医院(77%,27/35)(χ²=13.446,p<0.001)。不提供亚低温治疗的原因包括近年来 HIE 病例减少(39%)、冷却设备和治疗费用高(31%)、缺乏培训(26%)和安全性担忧(4%)。在提供亚低温治疗的医院中,27%(39/147)完全符合推荐方案。81%(222/273)的医院单独或联合使用有潜在神经保护作用的药物治疗 HIE 婴儿。91%的医院对 HIE 婴儿有长期的神经发育随访计划。
中国在 HIE 的诊断和治疗方面存在显著差异。亚低温治疗尚未成为全国新生儿 HIE 的常规治疗方法。未经证实的药物广泛用于 HIE 治疗。全国范围内 HIE 管理的标准化和亚低温治疗的推广为降低死亡率和改善受 HIE 影响儿童的长期神经发育结局提供了机会。